meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
6
mUC - L1 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus SoC
durvalumab based treatment
durvalumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
no study with result for this clinical condition